source
- Phase 3 trial shows Zealand-Boehringer obesity drug survodutide does not raise cardiovascular death riskThe Phase 3 SYNCHRONIZE-CVOT study found that survodutide, the joint obesity therapy from Zealand and Boehringer Ingelheim, was non‑inferior to placebo for cardiovascular death, indicating no added…
- Heron sells assets to CorMedix for $145M upfront, Faeth shares plungeHeron Therapeutics announced it has sold a portfolio of assets to CorMedix for an upfront cash payment of $145 million. The transaction gives CorMedix additional product candidates and expands its…